ついにでました、アジュバントニボのOS
効いてますね。
CheckMate274 adjuvant Nivo for MIUC

While at #GU24 , Daniel Geynisman, MD, discussed the #CheckMate274 trial and explained how the study utilized mixture cure models. Learn More: buff.ly/3Ul9j09

#EAU24 #checkmate274 +ve DFS early +ve OS #IM010 -ve for both. #AMBASSADOR +ve DFS early -ve OS. Perhaps too early. How do we explain. Subsequent therapy hard to read. dynamic. Maybe ctDNA+ trials will have clearer signals from more likely events.

#CheckMate274 #GU21 Matt Galsky
ASCO
Sumanta K. Pal, MD, FASCO Elizabeth Plimack MD Petros Grivas

FDA grants priority review to Opdivo as adjuvant treatment of urothelial carcinoma #bladdercancer #CheckMate274 ascopubs.org/doi/abs/10.120…

It‘been a while, but 🎉🔬 The 17th episode is out.
The last entity we tackled was the „incarnation“ of hot/inflamed urothelial carcinomas🔥🔥🔥🔥

But what do you know about PD-L1 testing ?
Today Matt Galsky presented important data of CheckMate274 at #EAU24 . PD-L1 positive…

.Ziad Bakouny, MD, MSc of Dana-Farber summarizes his highlights from #GU21 :
1️⃣ Advent of theranostics in PCa
2️⃣ Adjuvant nivo in high-risk muscle-invasive #urothelialcarcinoma : #CheckMate274
3️⃣ RCC studies using HIF-2a inhibitors
#pcsm #blcsm #kcsm

Just wrapped fantastic session on MIBC #GU21 . Andrea Apolo, M.D. james mckiernan take home:
✅ MRI for #bladdercancer is promising ✅ cCR not = pT0. ✅ pT0=best prognosis ✅ TMT 👍🏽in NAC responders ✅maintenance IO in metastatic dz ✅ CheckMate274🚨📢adjuvant Nivo in UC = improved DFS

Adjuvant Nivolumab finally shows OS benifit in MIUC . Checkmate274 . #EAU24 . adjuvant Pembrolizumab did not in Ambassador . Again why one IO works and other does not ? I don't know . Any one ? What to give these pts on progression after adjuvant Nivo ? Vinay Prasad MD MPH…

The OncoAlert 🚨 #GU24 DAY TWO Newsletter
FOCUS ON #BladderCancer
Comes out Tomorrow 7AM 🇺🇸 PST San Francisco

REGISTER TO GET IT AT
OncoAlert360.com or oncoalert.m-pages.com/nhMpwe/oncoale…

Discussing:
✅CheckMate 274♟️
✅FDG PET in MIBC ☢️
✅ABACUS 🧮
✅UNITE
✅GU Cancer…

⚡️ Checkmate 274 trial UPDATE at median follow-up 36.1 months. Median DFS 22.0 months Nivolumab vs 10.9 months w/placebo, [HR] 0.71.

✅Patients w/ PD-L1 ≥1%, Nivolumab median DFS 52.6 mo vs. 8.4 mo w/placebo (HR 0.52) 🤯
ASCO #GU23
OncoAlert

Dr Maria Jiang discusses results of the #CheckMate274 study on patients with muscle-invasive #urothelialcarcinoma . See her full analysis here: ow.ly/PHG850RmNFR

Watch all content from our Best of ASCO®️ GU & GI Cancers conference here: ow.ly/8etL50RmNFS

#MedOnc

👏👏New practice changing for #bladdercancer : Ph 3 trial (Checkmate-274) of adjuvant Nivolumab vs PBO after radical cystectomy for high-risk MIUBC! Stat.signf. mDFS both ITT pts and PD-L1 >1%. However IMvigor 010 trial was a negative study with similar design!🙄🙄 #GU21 ASCO 👇

《朗報》
【尿路上皮がん：術後治療】28日、オプジーボが「尿路上皮がんにおける術後補助療法」に関する適応拡大が承認された。この承認は、CheckMate 274試験の結果に基づく。
gantaisaku.net/checkmate-274/

Checkmate-274 is out in NEJM! Congrats Matt Galsky, Dean Bajorin and Team OncoAlert Targeted Oncology MJH Life Sciences® OncLive.com UroToday.com

nejm.org/doi/full/10.10…

BMS anunció que el uso de nivolumab de 240 mg cada 2 semanas o 480 mg cada 4 semanas (inyección para uso intravenoso) fue aprobado por la FDA para el tratamiento adyuvante de pacientes ➡️ bit.ly/3kv3p9d

#SEO #Oncologia #oncologos #FDA #carcinomaurotelial #CheckMate274

🎙️ In episode 309 of the Uromigos, Brian Rini, MD and Tom Powles talk with Matt Galsky about the #OS signal data from #CheckMate274 , which analyzed the use of #adjuvant #nivolumab in patients with #MIBC .

👉 Listen Here: buff.ly/3JioJM6

《朗報》
【尿路上皮がん：術後治療】3月3日の厚労省第二部会において「オプジーボ」の「尿路上皮がんにおける術後補助療法」への適応追加に対して承認報告される予定。
gantaisaku.net/checkmate-274/

Quite encouraging results with Checkmate-274, adjuvant nivolumab in high-risk MIBC (largely Cis-ineligible population). With HR 0.5-0.7 for DFS/RBS (depending on PD-L1 expression), I agree with the conclusion pending seeing all the data, ASCO #GU21
meetinglibrary.asco.org/record/195264/…

. #Checkmate274
How can it be that a clinical trial with pts w/ #BladderCancer from #LatinAmerica (🇦🇷 🇧🇷🇨🇱🇨🇴🇲🇽🇵🇪) and #US only reports 5 (1.4%) #black pts and 11 (3.1%) “others” out of a total of 709 pts ????? 🤯

Come on!!!

#MedTwitter #RaceEqualityWeek Bishal Gyawali